Interstitial lung disease in polymyositis and dermatomyositis

Current Opinion in Rheumatology

Volumn 12, Issue 6, 2000, Pages 501-508

  Hirakata, Michito ^a   Nagai, Sonoko ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHYLPREDNISOLONE; PREDNISONE; TACROLIMUS;

CLINICAL FEATURE; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; MORBIDITY; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW;

DERMATOMYOSITIS; HUMANS; LUNG DISEASES, INTERSTITIAL; POLYMYOSITIS;

EID: 0033735604     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200011000-00005     Document Type: Review

References (53)

1. Pulmonary disease in polymyositis/dermatomyositis: A clinicopathological analysis of 65 autopsy cases
2. Three types of pulmonary involvement in polymyositis
3. Interstitial pneumonitis in association with polymyositis and dermatomyositis
4. Interstitial pneumonitis in dermatomyositis
5. Interstitial lung disease in dermatomyositis: Clinicopathological study
6. Pulmonary disease in polymyositis/dermatomyositis
7. Interstitial lung disease in polymyositis and dermatomyositis: Clinical features and prognosis as correlated with histologic findings
8. Immunopathology of collagen vascular disease
9. Anti-KS: Identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease
10. Interstitial lung disease related to dermatomyositis: Comparative study with patients without lung involvement
11. Interstitial lung disease in patients with connective tisssue diseases
12. Polymyositis and diffuse interstitial lung disease: A review of the pulmonary histopathologic findings
13. Investigation of EB virus and cytomegalovirus in rapidly progressive interstitial pneumonitis in polymyositis/dermatomyositis by in situ hybridization and polymerase chain reaction
14. Polymyositis, pulmonary fibrosis, and hepatitis C
15. Polymyositis lung fibrosis, and cranial neuropathy in a patient with hepatitis C virus infection
16. Interstitial lung disease and cryoglobulinemia in polymyositis
17. Outcome in patients with interstitial lung disease and polymyositis-dermatomyositis: A subgroup with poor prognosis
18. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease
19. Interstitial lung disease in association with polymyositis-dermatomyositis: Long-term follow-up CT evaluation in seven patients
20. Interstitial lung disease of unknown cause: Disorders characterized by chronic inflammation of the lower respiratory tract (second of two parts)
21. Lung biopsy in rheumatoid arthritis
22. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis
23. Classification and recent advances in idiopathic interstitial pneumonia
24. Nonspecific interstitial pneumonia/fibrosis: Histologic features and clinical significance
25. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis
26. Idiopathic nonspecific interstitial pneumonia/fibrosis: Comparison with idiopathic pulmonary fibrosis and BOOP
27. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis
28. Idiopathic nonspecific interstitial pneumonia: Prognostic significance of cellular and fibrosing patterns. Survival comparison with usual interstitial pneumonia
29. Interstitial lung disease of unknown cause: Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts)
30. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease
31. Monitoring of serum KL-6 antigen in a patient with radiation pneumonia
32. New serum indicator of interstitial pneumonitis activity: Sialylated carbohydrate antigen KL-6
33. KL-6: A serum marker for interstitial pneumonia
34. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases
35. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis
36. Enzyme-linked immunosorbent assay using F(ab')2 fragment for the detection of human pulmonary surfactant protein D in sera
37. Immune manifestations of inflammatory muscle disease
38. Circulating KL-6 (MUC1 mucin) in patients with interstitial lung disease and anti- asparaginyl tRNA synthetase autoantibodies
39. Histological features of interstitial lung disease in patients with anti-glycyl tRNA synthetase autoantibodies
40. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetase in the absence of clinically apparent myositis
41. Anti-alanyl tRNA synthetase (PL-12) antibodies are associated with interstitial lung disease in Japanese patients
42. Myositis autoantibody inhibits histidyl-tRNA synthetase: A model for autoimmunity
43. Autoantibodies are anti-idiotype antibodies to antiviral antibodies
44. Circulating antibodies to lung protein(s) in patietns with cryptogenic fibrosing alveolitis
45. Localisation of a pulmonary autoantigen in cryptogenic fibrosing alveolitis
46. Detection of anti-cytokeratin 8 antibody in the sera of patients with cryptogenic fibrosing alveolitis and pulmonary fibrosis associated with collagen vascular disorders
47. Elevation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders
48. Detection of anti-ADAM 10 antibody in serum of a patient with pulmonary fibrosis associated with dermatomyositis
49. Rapidly progressive interstial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy
50. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis
51. Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis
52. Cyclosporine treatment for polymyositis/dermatomyositis: Is it possible to rescue the deteriorating cases with interstitial pneumonitis?
53. Tacrolimus in refractory polymyositis with interstitial lung disease